Zenas Biopharma (NASDAQ:ZBIO – Get Free Report) is expected to be posting its quarterly earnings results before the market opens on Tuesday, March 25th. Analysts expect Zenas Biopharma to post earnings of ($0.92) per share for the quarter.
Zenas Biopharma Stock Down 2.2 %
ZBIO opened at $8.33 on Monday. The firm has a market capitalization of $348.19 million and a price-to-earnings ratio of -2.35. Zenas Biopharma has a 12-month low of $5.83 and a 12-month high of $26.25.
Wall Street Analysts Forecast Growth
A number of equities analysts have issued reports on the company. Guggenheim reiterated a “buy” rating and issued a $45.00 price objective on shares of Zenas Biopharma in a report on Wednesday, March 12th. Wedbush assumed coverage on Zenas Biopharma in a report on Thursday. They issued an “outperform” rating and a $35.00 price objective for the company.
Zenas Biopharma Company Profile
Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company. The firm is mainly engaged in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.
See Also
- Five stocks we like better than Zenas Biopharma
- How to Calculate Stock Profit
- AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market
- How to Calculate Return on Investment (ROI)
- 3 ETFs to Ride the VIX Surge During Market Volatility
- How Investors Can Find the Best Cheap Dividend Stocks
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
Receive News & Ratings for Zenas Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zenas Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
